Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells

Journal of Cellular Physiology

Volumn 231, Issue 5, 2016, Pages 1097-1105

  Mirone, Giovanna ^a   Perna, Stefania ^b   Shukla, Arvind ^c   Marfe, Gabriella ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c D Y PATIL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBANILAMIDE DERIVATIVE; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PYRIDINE DERIVATIVE; REGORAFENIB; STEM CELL FACTOR RECEPTOR;

CELL PROLIFERATION; CHEMISTRY; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84956624621     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25206     Document Type: Article

References (50)

1. American cancer society: Cancer facts and figures, 2015. Atlanta, Ga: American Cancer Society. Available online. Last accessed January 7, 2015.
2. Andersson ER, Lendahl U. 2014. Therapeutic modulation of Notch signalling-Are we there yet? Nat Rev Drug Discov 13:357-378.
3. Candy PA, Phillips MR, Redfern AD, Colley SM, Davidson JA, Stuart LM, Wood BA, Zeps N, Leedman PJ. 2013. Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. Br J Cancer 109:1023-1030.
4. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. 2007. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 110:278-286.
5. Cheng YD, Yang HH, Chen GQ, Zhang ZC. 2013. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 7:1315-1322.
6. Dai Y, Wilson G, Huang B, Peng M, Teng G, Zhang D, Zhang R, Ebert MP, Chen J, Wong BC, Chan KW, George J, Qiao L. 2014. Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death Dis 5:e1170.
7. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, Warmuth M. 2007. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944-951.
8. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. 2012. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells. Cancer Cell 22:373-388.
9. Fender AW, Nutter JM, Bertrand FE, Sigounas G. 2015. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J Cell Biochem 16:2517-2527.
10. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study Group. 2013. Regorafenib monotherapy for previously treated metastatic colorectal cancer: An international, multicentre, prospective, randomised, placebo controlled phase 3 trial (CORRECT). Lancet 381:303-312.
11. Guo D, Ye J, Li L, Dai J, Ma D, Ji C. 2009. Down-regulation of Notch-1 increases co-cultured Jurkat cell sensitivity to chemotherapy. Leuk Lymphoma 50:270-278.
12. Hughes DP. 2009. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 152:479-496.
13. Izrailit J, Reedijk M. 2012. Developmental pathways in breast cancer and breast tumor-initiating cells: Therapeutic implications. Cancer Letts 317:115-126.
14. Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J, Zweidler-McKay PA. 2011. Notch/HES1-mediated PARP1 activation: A cell type-specific mechanism for tumor suppression. Blood 117:2891-2900.
15. Kunnimalaiyaan M, Traeger K, Chen H. 2005. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointestinal Liver Physiol 289:G636-G642.
16. Liu J, Fan H, Ma Y, Liang D, Huang R, Wang J, Zhou F, Kan Q, Ming L, Li H, Giercksky KE, Nesland JM, Suo Z. 2013. Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS ONE 8:e56141.
17. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. 2006. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66:4182-4190.
18. Magredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A. 2006. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254-259.
19. Maier MM, Gessler M. 2000. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new notch target genes. Biochem Biophys Res Commun 275:652-660.
20. Marfe G, Di Stefano C, Gambacurta A, Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi-Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB. 2011. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinibresistant chronic myeloid leukemia cells. Exp Hemat 39:653-665.
21. Marfe G, Mirone G, Perna S, Di Stefano C. 2015. The effects of Pyrrolo[1, 2-b] [1, 2, 5]benzothiadiazepines in MEC1 cells. J Cell Biochem 116:339-349.
22. Mazur PK, Riener MO, Jochum W, Kristiansen G, Weber A, Schmid RM, Siveke JT. 2012. Expression and clinicopathological significance of Notch signaling and cell-fate genes in biliary tract cancer. Am J Gastroenterol 107:126-135.
23. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, Schwartz GK. 2009. Y(small)-Secretase inhibitors abrogate oxaliplatininduced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69:573-582.
24. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. 2009. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 69:5015-5022.
25. Miyamoto S, Rosenberg DW. 2011. Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci 102:1938-1942.
26. Mungamuri SK, Yang X, Thor AD, Somasundaram K. 2006. Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66:4715-4724.
27. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zúñiga-Pflücker JC, Dominguez M, Ferrando AA. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13:1203-1210.
28. Polyak K, Weinberg RA. 2009. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273.
29. Ramdass B, Maliekal TT, Lakshmi S, Rehman M, Rema P, Nair P, Mukherjee G, Reddy BK, Krishna S, Radhakrishna Pillai M. 2007. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol 104:352-361.
30. Reedijk MOS, Zhang H, Chetty R, Tennert C, Dickson BC, Lockwood G, Gallinger SE. 2008. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 3:1223-1229.
31. Sade H, Krishna S, Sarin A. 2004. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 279:2937-2944.
32. Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D. 2014. Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer). Intern J Cancer 135:1487-1496.
33. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG. 2010. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance. Clin Cancer Res 16:6060-6070.
34. Sikandar S, Pate K, Anderson S, Dizon D, Edwards R, Waterman M, Lipkin S. 2010. Notch signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 70:1469-1478.
35. Singh RR, Kim JE, Davuluri Y, Drakos E, Cho-Vega JH, Amin HM, Vega F. 2010. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 24:1025-1036.
36. Stivarga 40 mg film-coated tablets. Summary of product characteristics. Berlin Bayer; 2013, 8.
37. Stylianou S, Clarke RB, Brennan K. 2006. Aberrant activation of notch signaling in human breast cancer. Cancer Res 66:1517-1525.
38. Suman S, Das TP, Ankem MK, Damodaran C. 2014. Targeting Notch signaling in colorectal cancer. Curr Colorectal Cancer Rep 10:411-416.
39. Ueo T, Imayoshi I, Kobayashi T, Ohtsuka T, Seno H, Nakase H, Chiba T, Kageyama R. 2012. The role of Hes genes in intestinal development, homeostasis and tumor formation. Development 139:1071-1082.
40. Villaronga MA, Lavery DN, Bevan CL, Llanos S, Belandia B. 2009. HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene 29:411-420.
41. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH. 2010. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 1806:258-267.
42. Wang Z, Li Y, Banerjee S, Sarkar FH. 2009. Emerging role of Notch in stem cells and cancer. Cancer Lett 279:8-12.
43. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. 2011. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255.
44. Wu WK, Wang XJ, Cheng AS, Luo MX, Ng SS, To KF, Chan FK, Cho CH, Sung JJ, Yu J. 2013. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol 86:251-277.
45. Xie M, He CS, Wei SH, Zhang L. 2013. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer 49:3559-3572.
46. Yang J, Weinberg RA. 2008. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 14:818-829.
47. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. 2012. SiRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pac J Cancer Prev 13:2485-2489.
48. Yin L, Velazquez OC, Liu ZJ. 2010. Notch signaling: Emerging molecular targets for cancer therapy. Biochem Pharmacol 80:690-701.
49. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. 2011. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer 58:682-689.
50. Zhang Y, Li B, Ji ZZ, Zheng PS. 2010. Notch1 regulates the growth of human colon cancers. Cancer 116:5207-5218.